



May 19, 2020

Ms. Ekaterine Tikaradze  
Minister of Internally Displaced Persons from the Occupied Territories,  
Labour, Health and Social Affairs of Georgia

Dear Minister Tikaradze:

Thank you for your 16 March letter to Gilead about access to remdesivir. We value greatly the historical partnership between Gilead and Georgia.

During this unprecedented pandemic, Gilead's overarching goal is to make remdesivir both accessible and affordable to governments and patients around the world, where authorized by regulatory authorities. Since January, Gilead has worked with speed, care and diligence to prepare for the possibility that the company's investigational antiviral remdesivir may be found effective against the virus that causes COVID-19. We are also in ongoing discussions with health authorities around the world to share the growing body of evidence for remdesivir and, through potential regulatory approvals, enable broad access to remdesivir for patients in urgent need of treatment.

In that regard, Gilead recently announced non-exclusive voluntary licensing agreements with five pharmaceutical manufacturers to further expand generic supply of the remdesivir. Under the agreements, Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan have the right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly to supply 127 countries, including Georgia. While at this stage detailed timelines for manufacturing are not known, we look forward to working with your organization and partners to enable access to remdesivir.

Our focus on providing access to medicines to people around the world has been and will continue to be unwavering. Today, an estimated 13 million people living with HIV in low-income countries are taking a Gilead-based regimen. This was made possible through our partnerships with low-cost, high-quality manufacturing partners located across the globe.

Finally, to further facilitate access in developing countries during this acute health crisis, Gilead is in advanced discussions with UNICEF to utilize their extensive experience providing medicines to low- and middle-income countries during humanitarian crises to deliver remdesivir using its well-established distribution networks.

As we have done with our medicines for HIV and viral hepatitis, Gilead is pursuing solutions that are collaborative and inclusive, with the aim of providing access to the greatest possible number of patients. For questions related to supply and production, you may contact Mr. Graeme Robertson at [graeme.robertson@gilead.com](mailto:graeme.robertson@gilead.com) or +44 20 8587 2228.

With sincere regards,

Clifford Samuel  
Senior Vice President  
Global Patient Solutions